ADMA Biologics (ADMA) Has Investors Asking A New Question

ADMA Biologics (ADMA) has drawn fresh attention after publishing peer reviewed data on its proprietary intravenous immune globulin manufacturing process. The report highlights impurity removal, higher immunoglobulin yield, and a reported absence of thromboembolic events.

Recent trading reflects that investors are reassessing ADMA Biologics in light of these clinical data. The share price has climbed 13.13% over the past month and 17.37% over the last 90 days, yet the year to date share price return is down 42.17%. Over the past five years, the total shareholder return has been very large, highlighting the potential benefits for those who held through earlier volatility.

Scan peer-reviewed progress like ADMA Biologics alongside a hand-picked 20 high quality undiscovered gems that may also be turning specialized science into growing commercial franchises.

After a sharp bounce on the new IVIG data, the question for ADMA Biologics is simple: Does the current valuation still offer an appealing skew between downside risk and upside potential for new money?

Most Popular Narrative: 39% Undervalued

Against a last close of $10.34, the most followed narrative pegs ADMA Biologics at a fair value of $17.00. This sets up a wide gap that hinges on how durable its margin structure and product mix really are.

The focus on higher margin ASCENIV within a more competitive standard IG market is shifting ADMA Biologics toward a product mix that has already supported adjusted EBITDA growth of 24% year over year on essentially flat first quarter 2026 revenue. This points to ongoing earnings leverage if this mix trend continues.

See why 51 investors see ADMA Biologics as 39% undervalued.

Result: Fair Value of $17 (UNDERVALUED)

Still, concentrated reliance on a few therapies and ongoing lawsuits tied to ASCENIV distribution practices could unsettle the ADMA Biologics story if conditions worsen.

Find out about the key risks to this ADMA Biologics narrative.

Next Steps

If this mix of enthusiasm and caution around ADMA Biologics leaves you on the fence, dig into the numbers now and test the thesis yourself. To see what others are highlighting as upside, review the 3 key rewards

Looking for more investment ideas beyond ADMA Biologics?

If ADMA Biologics has sharpened your curiosity, do not stop here. Broaden your watchlist now so you are not chasing the next opportunity after it has already moved.

• Spot potential mispricing early by running through a curated set of 32 high quality undervalued stocks that might trade below their assessed worth based on fundamentals.
• Protect your downside by filtering for 32 resilient stocks with low risk scores that pair steadier financial profiles with more measured risk scores.
• Get ahead of the crowd by scanning a focused 20 high quality undiscovered gems that could be flying under most investors' radars.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com